Results 161–180 of 305 for speaker:Lord Freyberg

Written Answers — Department of Health: Cancer (19 Jan 2016)

Lord Freyberg: To ask Her Majesty’s Government what molecular testing takes place in the UK in mesothelioma and other rare cancers; and how that compares to more common cancers such as breast, lung or colorectal cancer.

Written Answers — Department of Health: Cancer (19 Jan 2016)

Lord Freyberg: To ask Her Majesty’s Government what assessment the National Institute for Health Research Horizon Scanning Research and Intelligence Centre and Genomic England have made of the potential of precision oncology for less common cancers.

Written Answers — Department of Health: Cancer (19 Jan 2016)

Lord Freyberg: To ask Her Majesty’s Government what assessment the National Institute for Health Research Horizon Scanning Research and Intelligence Centre and Genomic England have made of the barriers to adopting national molecular pathology.

Written Answers — Department of Health: Pathology (19 Jan 2016)

Lord Freyberg: To ask Her Majesty’s Government what progress the Chief Scientific Officer of NHS England is making towards the introduction of a national molecular pathology service.

National Health Service — Motion to Take Note (14 Jan 2016)

Lord Freyberg: My Lords, this debate is about present and future demand and how we best manage it. In doing so, we need to include all rare disease, not just the big killers. Individual rare diseases may not kill many, but collectively they are a significant part of the disease burden. Mesothelioma is such a disease. In the recent mesothelioma debate, the Government confirmed that 60,000 are expected to die...

Written Answers — Department of Health: Cancer (16 Dec 2015)

Lord Freyberg: To ask Her Majesty’s Government for (1) England, (2) Scotland, and (3) Wales, how much was spent per capita on cancer services, and what is the national one-year cancer survival rate as a percentage of new patients for the most recent year available.

Written Answers — Department of Health: Cancer (14 Dec 2015)

Lord Freyberg: To ask Her Majesty’s Government what assessment they have made of (1) how much (a) England, (b) Scotland, (c) Wales, (d) Sweden, (e) the Netherlands, (f) France, (g) Denmark, (h) Belgium, and (i) Italy, spent per capita on cancer services, and (2) the national one-year cancer survival rates as a percentage of new patients for each of those countries, for the most recent year for which...

Written Answers — Department of Health: Prostate Gland: Surgery (10 Dec 2015)

Lord Freyberg: To ask Her Majesty’s Government how many NHS England Trusts provide prostate surgery; how many of those track their incontinence rates after prostate surgery; of those hospitals that track outcomes, what is the average rate of post-surgical incontinence; what assessment they have made of whether survey-based research could be used to estimate the incontinence rate of those hospitals that do...

Written Answers — Department of Health: Cancer (10 Dec 2015)

Lord Freyberg: To ask Her Majesty’s Government what assessment they have made of the performance of the NHS England cancer genetic testing service compared to the French system run by the Institute Nationale du Cancer in terms of equality of access as measured by the percentage of eligible patients who actually receive tests for (1) breast cancer, (2) lung cancer, (3) colorectal cancer, and (4) melanoma.

Written Answers — Department of Health: Cancer (10 Dec 2015)

Lord Freyberg: To ask Her Majesty’s Government what percentage of stage 2b cancer or higher patients in (1) tertiary, and (2) secondary, care centres were tested by NHS England in 2014 for genetic mutations that can confer resistance to targeted cancer therapies, in particular (a) AR amplification mutations, (b) ESR1 activation mutations, (c) PIK3CA mutations, (d) KRAS activation mutations, (e) EGFR...

Written Answers — Department of Health: Cancer (10 Dec 2015)

Lord Freyberg: To ask Her Majesty’s Government how many business cases were created in NHS England trusts in 2014 that related to the business justification for introducing new tumour genetic tests; when reviewing those business cases, what percentage of trusts allowed drugs budget savings to be included, given that such savings occur outside the underlying NHS tariff; and what is their estimate of the...

Written Answers — Department of Health: Cancer (10 Dec 2015)

Lord Freyberg: To ask Her Majesty’s Government what is the average turnaround time for cancer genetic tests relating to (1) breast cancer, (2) lung cancer, (3) colorectal cancer, and (4) melanoma, measured from biopsy to a discussion of the results with the patient, in (a) tertiary care centres, (b) secondary care centres with in-house testing, and (c) secondary care centres with third-party testing.

Written Answers — Department of Health: Cancer (3 Dec 2015)

Lord Freyberg: To ask Her Majesty’s Government what percentage of NHS tertiary care centres provide in-house tumour genetic testing in (1) breast cancer, (2) colorectal cancer, (3) lung cancer, and (4) melanoma.

Written Answers — Department of Health: Cancer (3 Dec 2015)

Lord Freyberg: To ask Her Majesty’s Government what percentage of NHS secondary care centres provide in-house tumour genetic testing in (1) breast cancer, (2) colorectal cancer, (3) lung cancer, and (4) melanoma.

Written Answers — Department of Health: Cancer (3 Dec 2015)

Lord Freyberg: To ask Her Majesty’s Government what percentage of NHS secondary care centres provide third-party tumour genetic testing in (1) breast cancer, (2) colorectal cancer, (3) lung cancer, and (4) melanoma.

Written Answers — Department of Health: Cancer (3 Dec 2015)

Lord Freyberg: To ask Her Majesty’s Government what percentage of NHS secondary care centres do not provide tumour genetic testing in (1) breast cancer, (2) colorectal cancer, (3) lung cancer, and (4) melanoma.

Written Answers — Department of Health: Cancer (3 Dec 2015)

Lord Freyberg: To ask Her Majesty’s Government what percentage of eligible patients across England received access in (1) 2013, and (2) 2014, to the full range of NICE approved tumour genetic testing for (1) breast cancer in NHS tertiary centres, (2) breast cancer in NHS secondary centres, (3) colorectal cancer in tertiary centres, (4) colorectal cancer in secondary centres, (5) lung cancer in tertiary...

Mesothelioma (Amendment) Bill [HL]: Second Reading (20 Nov 2015)

Lord Freyberg: My Lords, I support the Bill and I, too, congratulate the noble Lord, Lord Alton, on bringing this issue back to Parliament following its narrow defeat in this House in 2013. Like the noble Lord, Lord McNally, my interest in this subject is personal. Just over three years ago, in June 2012, my sister, Annabel Freyberg, a journalist, was diagnosed with mesothelioma. Her diagnosis followed one...

Written Answers — Department for Education: Vocational Education: Design (9 Nov 2015)

Lord Freyberg: To ask Her Majesty’s Government whether they intend to take steps to increase the number of vocational pathways in design disciplines, and if so, by how many.

Written Answers — Department for Business, Innovation and Skills: Design: Apprentices (5 Nov 2015)

Lord Freyberg: To ask Her Majesty’s Government how many apprenticeships there are in the field of design; and whether they plan to take steps to increase the number.


<< < 1 2 3 4 5 6 7 8 9 10 > >>

Create an alert

Did you find what you were looking for?

Advanced search

Find this exact word or phrase

You can also do this from the main search box by putting exact words in quotes: like "cycling" or "hutton report"

By default, we show words related to your search term, like “cycle” and “cycles” in a search for cycling. Putting the word in quotes, like "cycling", will stop this.

Excluding these words

You can also do this from the main search box by putting a minus sign before words you don’t want: like hunting -fox

We also support a bunch of boolean search modifiers, like AND and NEAR, for precise searching.

Date range

to

You can give a start date, an end date, or both to restrict results to a particular date range. A missing end date implies the current date, and a missing start date implies the oldest date we have in the system. Dates can be entered in any format you wish, e.g. 3rd March 2007 or 17/10/1989

Person

Enter a name here to restrict results to contributions only by that person.

Section

Restrict results to a particular parliament or assembly that we cover (e.g. the Scottish Parliament), or a particular type of data within an institution, such as Commons Written Answers.

Column

If you know the actual Hansard column number of the information you are interested in (perhaps you’re looking up a paper reference), you can restrict results to that; you can also use column:123 in the main search box.